AYTU has 36-month beta value of -1.39. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AYTU is 5.94M, and currently, short sellers hold a 3.25% ratio of that float. The average trading volume of AYTU on November 15, 2024 was 26.12K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AYTU) stock’s latest price update
Aytu BioPharma Inc (NASDAQ: AYTU)’s stock price has dropped by -11.17 in relation to previous closing price of 1.75. Nevertheless, the company has seen a loss of -14.61% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-13 that Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum – IR, Lytham Partners Josh Disbrow – Chief Executive Officer Mark Oki – Outgoing Chief Financial Officer Ryan Selhorn – Chief Financial Officer Conference Call Participants Naz Rahman – Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call.
AYTU’s Market Performance
AYTU’s stock has fallen by -14.61% in the past week, with a monthly drop of -32.24% and a quarterly drop of -41.29%. The volatility ratio for the week is 15.43% while the volatility levels for the last 30 days are 8.92% for Aytu BioPharma Inc The simple moving average for the past 20 days is -20.43% for AYTU’s stock, with a -42.87% simple moving average for the past 200 days.
Analysts’ Opinion of AYTU
Many brokerage firms have already submitted their reports for AYTU stocks, with Cantor Fitzgerald repeating the rating for AYTU by listing it as a “Overweight.” The predicted price for AYTU in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on March 30, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AYTU reach a price target of $3. The rating they have provided for AYTU stocks is “Buy” according to the report published on May 29th, 2020.
AYTU Trading at -30.25% from the 50-Day Moving Average
After a stumble in the market that brought AYTU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.07% of loss for the given period.
Volatility was left at 8.92%, however, over the last 30 days, the volatility rate increased by 15.43%, as shares sank -32.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.42% lower at present.
During the last 5 trading sessions, AYTU fell by -14.61%, which changed the moving average for the period of 200-days by -43.22% in comparison to the 20-day moving average, which settled at $1.9479. In addition, Aytu BioPharma Inc saw -45.42% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AYTU
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.69 for the gross margin
The net margin for Aytu BioPharma Inc stands at -0.08. The total capital return value is set at -0.09. Equity return is now at value -21.39, with -5.33 for asset returns.
Based on Aytu BioPharma Inc (AYTU), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.27. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 4.71.
Currently, EBITDA for the company is -1.01 million with net debt to EBITDA at 5.69. When we switch over and look at the enterprise to sales, we see a ratio of -0.12. The receivables turnover for the company is 3.26for trailing twelve months and the total asset turnover is 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.99.
Conclusion
To put it simply, Aytu BioPharma Inc (AYTU) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
